The race for hydroxamate-based zirconium-89 chelators

Irene V.J. Feiner, Marie Brandt, Joseph Cowell, Tori Demuth, Daniëlle Vugts, Gilles Gasser, Thomas L. Mindt*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Metallic radionuclides conjugated to biological vectors via an appropriate chelator are employed in nuclear medicine for the diagnosis (imaging) and radiotherapy of diseases. For the application of radiolabeled antibodies using positron emission tomography (immunoPET), zirconium-89 has gained increasing interest over the last decades as its physical properties (t1/2 = 78.4 h, 22.6% β+ decay) match well with the slow pharmacokinetics of antibodies (tbiol . = days to weeks) allowing for late time point imaging. The most commonly used chelator for89Zr in this context is desferrioxamine (DFO). However, it has been shown in preclinical studies that the hexadentate DFO ligand does not provide89Zr-complexes of sufficient stability in vivo and unspecific uptake of the osteophilic radiometal in bones is observed. For clinical applications, this might be of concern not only because of an unnecessary dose to the patient but also an increased background signal. As a consequence, next generation chelators based on hydroxamate scaffolds for more stable coordination of89Zr have been developed by different research groups. In this review, we describe the progress in this research field until end of 2020, including promising examples of new candidates of chelators currently in advanced stages for clinical translation that outrun the performance of the current gold standard DFO.

Original languageEnglish
Article number4466
JournalCancers
Volume13
Issue number17
DOIs
Publication statusPublished - Sept 2021

Cite this